Susceptibility to LAK-mediated Cytotoxicity of Multidrug-resistant Variants of the Human RAJI Cell Line is Not Related to Expression of Major Cellular Adhesion Molecules by Treichel, Robin S.
Susceptibility to LAK-mediated Cytotoxicity of Multidrug-resistant Variants
of the Human RAJI Cell Line is Not Related to Expression of Major Cellular
Adhesion Molecules1
ROBIN S. TREICHEL, Department of Biology, Oberlin College, Oberlin, OH 44074-1082
ABSTRACT. The association of multidrug resistance (MDR) with resistance to lysis by natural killer (NK) and
lymphokine-activated killer (LAK) cells is controversial. To address this issue further, drug-resistant variants
of a human Burkitt lymphoma cell line (RAJI) were developed in vitro by intermittent exposure to
Adriamycin® (R/ADR) or to etoposide (R/VP-16). The RAJI cell line was selected because it is a
standard LAK-susceptible target. Both MDR lines as well as the parent cell line were found to be resistant to
NK-mediated lysis, but highly susceptible to LAK-mediated lysis. Notably, R/ADR cells, which
express high levels of P-glycoprotein (P-gp), were nearly eight-times more susceptible to LAK-mediated
lysis than parental cells, whereas R/VP-16 cells, which are P-gp-negative, were equally as susceptible as
parental cells. Immunofluorescence analyses revealed that expression of cellular adhesion molecules that
have been reported to control susceptibility of targets to NK- and LAK-lysis (ICAM-1, LFA-1, LFA-3,
and MHC class I) did not differ significantly between the RAJI parent line and drug-resistant variants. This
finding suggests that the increased LAK-sensitivity of R/ADR results from alterations which affect post-
binding stages of the LAK lytic pathway.
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INTRODUCTION
The development of resistance to anticancer agents by
tumor cells is a common and serious clinical problem. In
vitro selection of cell lines with natural product agents
such as doxorubicin (Adriamycin®, ADR), vincristine or
etoposide (VP-16) has produced sublines which are
resistant to a variety of structurally and functionally
unrelated agents (Curt et al. 1984, Danks et al. 1987). This
phenotype is termed multidrug-resistance (MDR) and
approximates that seen clinically (Curt et al. 1984).
Frequently, MDR is associated with increased expression
of a Mr 170,000 plasma protein, termed the P-glycoprotein
(P-gp), which apparently functions as an efflux pump to
reduce the intracellular accumulation of natural product
agents. P-gp-associated MDR has been demonstrated
clinically in several malignancies, including acute leukemia
(Fojo 1989, Kuwazuru 1990, Mattern et al. 1989). Another
form of MDR is associated with an alteration in DNA
topoisomerase II activity, resulting in fewer drug-
induced breaks of DNA strands (Glisson et al.
1986). Cells with this "atypical" form of MDR (Danks
et al., 1987) are resistant to anthracyclines and
epipodophyllotoxins, but in contrast to cells with P-gp-
associated MDR, retain susceptibility to Vinca alkaloids,
do not over-express P-gp, and do not exhibit reduced
intracellular drug accumulation. Cells selected for ADR-
resistance may have additional mechanisms which
contribute to their MDR phenotype including reduced
drug uptake, enhanced detoxification by glutathione-S-
transferases (Singh et al. 1989) and early DNA repair
(Baas et al. 1990, Deffie et al. 1988).
Adoptive immunotherapy with interleukin-2 (IL-2)-
activated lymphocytes (LAK) has been proposed as an
'Manuscript received 24 August 1992 and in revised form 12
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approach to overcome MDR (Adler et al. 1988, Higuchi et
al. 1989, Lotzova et al. 1990). Activity of LAK cells has been
shown to be mediated primarily by natural-killer (NK)
cells (Lotzova et al. 1990). Although NK cells are capable
of spontaneously killing a variety of tumor cells, activation
with IL-2 enhances their activity and increases the range
of susceptible tumor targets (Grimm et al. 1982). An
important question is whether tumor cells which exhibit
MDR remain susceptible to lysis by LAK cells. There have
been several recent studies to address this problem
(Harker et al. 1990, Kimmig et al. 1990, Ohtsu et al. 1989,
Scheper et al. 1991), but the studies have been limited in
number and have yielded conflicting results.
To further examine the possible relationship between
MDR and LAK susceptibility, we developed two MDR
sublines of the human Burkitt lymphoma cell line RAJI.
The RAJI cell line was selected because it is a
standard target used for the study of LAK activity.
Our parental and drug-resistant lines were compared
for susceptibility to LAK lysis. Because increased
expression of P-gp has been associated with altered cell-
surface expression of the cellular adhesion molecules
which play a role in NK/LAK target-cell interactions
(Robertson et al. 1990, Scheper et al. 1991), we also
examined the expression of major adhesion molecules
on our parent and drug-resistant cells.
MATERIALS AND METHODS
Chemicals and Supplies
RPMI 1640 media with and without phenol red were
purchased from GIBCO (Grand Island, NY); fetal bovine
serum was from Flow Laboratories (McLean, VA) and from
Hyclone Laboratories (Logan, UT). Etoposide (VP-16,
VePesid®) was generously supplied by Bristol-Myers
(Evansville, IN) and ADR was generously supplied by
Adria Laboratories (Dublin, OH); vincristine (Oncovin®)
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was purchased from Lilly (Indianapolis, IN). The tetrazolium
salt 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
I(phenylamino)carbonyll2//-tetrazolium hydroxide was
obtained from Polysciences, Inc. (Warrington, PA).
Phenazine methosulfate, triton-X, penicillin, streptomycin,
ficoll-hypaque and IL-2 were obtained from Sigma (St.
Louis, MO). Gammascint™ scintillation fluid was obtained
from National Diagnostics (Manville, NJ). The C219
monoclonal antibody was purchased from Centocor
(Malvern, PA); DAKO-CDlla, DAKO-CD18, DAKO-CD56,
and DAKO-HLA-A,B,C were purchased from DAKO
(Carpinteria, CA); CT-CD29 and CT-CD54 from Biosource
International (Camarillo, CA); AI-CD58 from AMAC, Inc.
(Westbrook, ME); 13 from Coulter (Hialeah, FL); and the
murine IgG2a myeloma protein (UPC 10) from Organon
Teknika (Durham, NC). Fluorescein-conjugated goat anti-
mouse IgG and bovine serum albumin (Cohn fraction V)
were purchased from Boehringer Mannheim Biochemicals
(Indianapolis, IN).
Cell Lines
The Burkitt lymphoma cell line RAJI was obtained from
the American Type Culture Collection (CCL 86, Rockville,
MD). The MDR sublines CEM/VLBim and CEM/VM-1
100
(Beck et al. 1987, Danks et al. 1987) were provided by
Dr. W. T. Beck, St. Jude Children's Research Hospital
(Memphis, TN). Cells were grown as a suspension
culture in RPMI 1640 medium supplemented with
10% FBS; penicillin, 50 IU/ml; streptomycin, 50 Lig/
ml; and for CEM variants, 10 mM HEPES (N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid). Cultures
were maintained at 37°C in a humidified atmosphere of
5% C07 in air and sub-cultured every two days. Routine
testing for Mycoplasma contamination proved negative.
The R/ADR subline was derived by culturing parent
cells in 10 mM ADR and gradually increasing the
concentration to 60 nM over a period of 10 months. The
R/VP-16 subline was derived over a period of 6 months by
increasing VP-16 from 10 nM to a final concentration of
400 nM. Growth rates and viabilities of the resistant
sublines are equivalent to those of the parent line.
A large number of ampoules of the resistant cultures
were frozen. In order to prevent genetic drift, cells were
maintained in culture for no more than two months and
then were replaced with freshly thawed cultures. Thawed
drug-resistant cells were cultured with selecting drug for
four to seven days, but were always maintained without
drug for at least one week prior to assay.
Drug Sensitivity Studies
The sensitivities of the drug-resistant and parent cell
lines to ADR, vincristine, and VP-16 were compared using
a modification of a soluble tetrazolium/formazan assay
(Scudiero et al. 1988). Logarithmically growing cells were
washed, resuspended in RPMI 1640 without phenol red
supplemented with 10% FBS and antibiotics and incubated
at a final concentration of 2.5 x lOVml with drug in a total
volume of 200 |il in wells of 96-well flat-bottom microplates.
Anti-cancer compounds were diluted in 0.9% saline prior
to addition to wells. After three days, 100 jJ.1 of a freshly
prepared solution of phenazine methosulfate (0.03 mM) in
XTT (1 mg/ml in serum-free medium) was added per well
and incubation continued for 3-5 hours. Plates were then
shaken and the absorbance measured at 450 nm with a
Vmax microplate reader (Molecular Devices, Menlo Park,
CA). Assay points were determined from six replicate
wells and experiments were repeated at least three times.
Wells containing phenazine methosulfate-XTT in medium
without cells served as the plate blank. Parent and drug-
resistant lines were always tested in parallel for sensitivity
to a particular compound. The drug concentration was
determined which reduced by 50% (IC.()) the A,_() in wells
containing drug as compared to control wells without
drug. Relative resistance was calculated by dividing the
IC of the resistant line by the IC.() of the parent line.
Immunoiluorescence Analysis
The C219 monoclonal antibody was used to detect a
conserved epitope of the cytoplasmic domain of P-gp
(Kartner et al. 1985). Drug-resistant cells, parental cells,
and cell mixtures were evaluated by indirect
immunofluorescence using a slight modification of the
previously described procedure (Kartner et al. 1985).
Fixed cells (106) were incubated overnight at 4°C
with 1 (ig C219, washed twice and then incubated
for one hour at 4°C with FITC-anti-mouse IgG
diluted 1/60. Washed cells were then resuspended
in freshly prepared 50% glycerol in PBS containing
20 mg/ml l,4-diazobicyclo-(2,2,2)octane and examined
on a Nikon epifluorescence microscope. Background
staining, determined using the isotype-matched murine
myeloma protein UPC 10 as primary antibody, was
uniformly weak with all lines. To calibrate the staining
reactions, the P-gp-positive CEM/VLBH)() and P-gp-negative
CEM/VM-1 cells which exhibit known degrees of P-gp
expression (Beck et al. 1987) were simultaneously stained
with C219 and isotype antibody. Experiments were
performed twice with identical results.
Expression of adhesion molecules was determined
using a standard indirect immunofluorescence assay (Stong
et al. 1985) with the anti-ICAM-1 antibody CT-CD54, the
anti-LFA-1 antibodies DAKO-CDlla and DAKO-CD18,
the anti-LFA-3 antibody AI-CD58, the anti-human integrin
E-l chain antibody CT-CD29, the anti-human natural killer
cell antibody DAKO-CD56 as well as the anti-MHC class I
and class II framework antibodies DAKO-HLA-A,B,C and 13.
Monoclonal antibodies were used at concentrations
recommended by the manufacturers. At least 100 cells were
evaluated for each sample; fluorescence intensity was
subjectively graded on a scale from weak (+) to very strong
(+ + ++). Experiments were performed twice with
similar results.
NK and LAK Cytotoxicity Assays
Drug-resistant variants were cultured in drug-free
medium for at least two weeks prior to use as targets in a
standard 51Cr-release assay. Mononuclear cells from
peripheral blood of healthy adult volunteers were isolated
by ficoll-hypaque gradient centrifugation, and plastic
nonadherent cells were used directly as effectors (NK) or
stimulated for five days with 100 units/ml of recombinant
human IL-2 (LAK effectors). Stimulated effector cells were
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washed before use. Varying numbers of effector cells were
incubated in triplicate with 10,000 or 20,000 51Cr-labeled
targets in 200 |Lll in microtiter plates for four hours
at 37°C in a humidified atmosphere of 5% CO2 in air. Plates
were then centrifuged (500 x g, 10 min) and 100 LLI of
supernatant from each well was placed in a vial with
3 ml of scintillation fluid and radioactivity determined
with a Beckman scintillation counter. Percent specific
cytotoxicity was calculated as follows:
specific lysis =
test cpm - spontaneous cpm
total cpm - spontaneous cpm
X 100%.
Spontaneous 51Cr release was determined by incubating
target cells in medium without effectors. Total counts were
determined by incubating target cells in 1% Triton-X; total
cpm ranged from 7,600-48,900 depending on the target
line and number of cells plated. Spontaneous release was
always less than 10% of total 51Cr release. One lytic unit was
defined as the number of effector cells required to lyse 40%
of 10,000 targets; the number of lytic units per 108 effectors
(LU40/108) was calculated. Drug-resistant and drug-sensitive
cell line pairs were always tested in parallel within the
same experiment. Three experiments using effectors from
different donors yielded results which were essentially
identical. The statistical significance of differences between
drug-resistant sublines and the parent cell line was
determined by Student's t test for paired samples.
RESULTS
Cross-resistance to Anti-cancer Agents
Parent and drug-resistant cell lines were evaluated for
sensitivity to several anti-cancer agents encompassed within
the spectrum of MDR (Table 1). The R/ADR and R/VP-16
lines were 7.4-fold and 52.1-fold, respectively, more resistant
than RAJI to their selecting agents. Each subline also
exhibited resistance to additional drugs. R/ADR exhibited
low-level resistance to vincristine (3.2-fold) and surprisingly
was more resistant to VP-16 (22-fold) than to the selecting
agent ADR. The R/VP16 line, in contrast, exhibited cross-
resistance to ADR (5.9-fold) but not to vincristine (1.1-fold).
TABLE 1
Drug sensitivity of drug-resistant sublines derived from the human
Burkitt lymphoma line RAJI.
Cell Line Adriamycin
ICW (nM)a
Vincristine Etoposide
RAJI
R/ADR
R/VP-16
48.6 ± 2.6
357.7 ± 12.3
284.7 ± 12.5
1.68 ±0.11
5.31 ± 0.37
1.91 ±0.16
179 ± 21
3947 ± 587
9325 ± 1563
aThe IC.() is the concentration of chemotherapeutic agent that inhibits cell
growth by 50% in the XTT colormetric assay. Lymphoma cells in six
replicate wells at 2.5 x 10' cells/well were incubated with 8-10 concen-
trations of anti-cancer agent for three days at 37°C. XTT with phenazine
methosulfate was added and incubation continued for 3-5 hours
followed by determination of the A45O. Parent and variant sublines were
always tested in parallel. Values represent the mean ± s.d. of at least three
independent experiments.
P-Glycoprotein Expression
The P-gp-specific C219 monoclonal antibody stained
RAJI cells more intensely than did the control isotypic
antibody and produced a fluorescence intensity which
was slightly but reproducibly stronger than that observed
with P-gp-negative CEM/VM-1 cells. R/ADR reacted strongly
with C219; stained cells exhibited a fluorescence intensity
which was much greater than that of C219-stained RAJI
cells and nearly as bright as that of identically treated CEM/
VLB100 cells. In contrast, R/VP-16 stained no more intensely
with C219 than with control isotype antibody. These
results indicate that R/VP-16 is negative, RAJI is weakly
positive and R/ADR is strongly positive for P-gp expression.
Susceptibility to NK- and LAK-mediated Cytotoxicity
As expected, the drug-resistant and parental cells were
resistant to NK cell-mediated cytotoxicity (Fig. 1); less than
10% specific lysis was observed in a 4-hr 51Cr-release assay
at even the highest effector:target ratios. Stimulation of
effectors with IL-2 for 5 days markedly increased lytic
activity against all three targets. At an effector:target ratio
of 40:1 all targets showed at least 50% lysis. Notably,
R/ADR was markedly more susceptible than the parent
line with effectors from all donors tested (P < 0.001).
Comparison of activity expressed as lytic units indicates
that R/ADR (LU4(/108 = 262,467) was 7- to 8-times more
susceptible to LAK-lysis than RAJI (LU40/108 = 33,367) or
R/VP-16 (LU40/108 = 37,037).
Cell Surface Expression of Adhesion Molecules
No marked differences in expression of adhesion
molecules were detected between parental and resistant
cell lines. CD29 expression varied somewhat with moderate
expression (++) by RAJI and R/ADR and low-level
expression (+) by R/VP-16. For the other antigens assayed,
no differences between parent and resistant cells were
observed in percent positive cells or in fluorescence
intensity. All cell lines strongly expressed MHC class I
(++++), MHC class II (++++), and ICAM-1 (+++) molecules.
Cells also expressed low levels of LFA-3 (+) and LFA-1 (+),
but were negative for the human NK cell antigen CD56.
DISCUSSION
Experimental data suggest that adoptive immunotherapy
with IL-2/LAK cells may be a useful treatment for leukemia
(Adler et al. 1988, Higuchi et al. 1989, Lotzova et al. 1990).
Given the proven efficacy of chemotherapy, most patients
who become candidates for immunotherapy will have
failed previous chemotherapeutic regimens. In these
patients, immune effector cells will likely encounter tumor
populations which have survived and therefore may be
resistant to the cytotoxic effect of drugs. Several recent
reports have described adult and pediatric leukemia
patients who exhibit MDR associated with amplification of
the mdrl gene and increased expression of P-gp (Fojo
1989, Kuwazuru et al. 1990, Mattern et al. 1989). Therefore,
the question of whether MDR tumor cells remain susceptible
to cell-mediated lysis bears considerable clinical
significance. The present study was undertaken to examine
this question.
Results of the present study clearly demonstrate that an
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FIGURE 1. Comparison of the susceptibility of RAJI ( • ) and the MDR variants R/ADR ( • ) and R/VP-16 ( • ) to lysis by NK cells (open symbols)
and LAK cells (solid symbols). Unstimulated peripheral blood lymphocytes were separated by ficoll-hypaque density centrifugation and tested directly
as effectors of NK lytic activity against 10,000 or 20,000 51Cr-labeled lymphoma targets. Peripheral blood lymphocytes from the same donors were
stimulated for five days with 100 IU/ml IL-2 and used as LAK effectors. After four hours incubation at 37°C, aliquots were assayed to determine specific
51Cr-release. Cytotoxicity is expressed as the average percentage of specific lysis calculated as described in Materials and Methods. Each point represents
the mean of determinations with three normal donors, each set up in triplicate; standard deviations were always less than 5%.
MDR phenotype does not invariably confer resistance to
the cytolytic activity of LAK cells. The P-gp-negative, MDR
variant R/VP-16 was found to be as susceptible to LAK lysis
as the parent RAJI lymphoma line (Table 1, Fig. 1).
Moreover, the P-gp-positive variant R/ADR was nearly 8-
times more susceptible than the parent line.
The present results contrast with recent reports showing
an inverse relationship between the level of P-gp expression
and the susceptibility to LAK lysis of human leukemic cell
lines (Kimmig et al. 1990). Instead, our results parallel the
findings of Allavena et al. (1987) who reported that LAK
cells lyse MDR human colon adenocarcinoma cell lines at
least as well as the parental cell line. As in our model
system, their "drug-sensitive" parental cell line (L0V0/H)
expressed low levels of P-gp (Rivoltini et al. 1990). This
low level expression suggests that the parent lines are
themselves somewhat drug-resistant and thus makes it
difficult to draw firm conclusions regarding the susceptibility
of parental versus "drug-resistant" cells. Rivoltini et al.
(1990) have demonstrated that the P-gp molecule does not
directly alter target LAK susceptibility. However, ADR-
selected P-gp-positive variants may harbor additional
alterations which contribute to the drug resistance
phenotype (Baas et al. 1990, Deffie et al. 1988). Such as-
yet unidentified alterations may also play a role in the
increased LAK sensitivity of R/ADR.
In vitro incubation of NK cells with IL-2 increases
surface expression of the cell adhesion molecules LFA-1
(CD1WCD18), CD2, ICAM1 (CD54), LFA-3 (CD58) and
the NK cell-associated antigen NKH-1 (CD56) (Robertson
et al. 1990). Altered sensitivity of target cells to NK or LAK
lysis, therefore, might be associated with changes
in the expression of the ligands of these adhesion
molecules. Scheper et al. (1991) recently reported that
LFA-3 and ICAM-1 expression was reduced in two P-gp-
positive MDR sublines. However, in the current study
immunofluorescence analyses revealed no differences in
percent positive cells or in fluorescence intensity between
RAJI cells and the two MDR sublines. These results indicate
that an increase (R/ADR) or decrease (R/VP-16) in P-gp
expression does not invariably lead to altered expression
of the adhesion molecules known to be associated with
NK/LAK lysis.
Parent and MDR RAJI lines were resistant to NK lysis;
this resistance may result from the strong expression on all
cells of MHC class I molecules, which have been shown
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to inhibit NK cell function in certain model systems
(Storkus and Dawson 1991). The equivalent expression of
adhesion molecules by R/ADR and RAJI suggests that the
elevated LAK susceptibility of R/ADR is probably not a
result of enhanced conjugate formation between targets
and effector cells. Perhaps R/ADR cells more readily
activate the LAK lytic pathway or are more susceptible to
the cytotoxic factors released by LAK effectors.
The results of the current study support the use of
immunotherapy as a potentially valuable treatment
modality. Further studies are needed to explain the
underlying basis for the variable LAK sensitivity of MDR
cells that has been reported by various investigators.
Characterization of such paired sensitive/resistant cell
lines may ultimately contribute to our basic understanding
of the mechanism by which NK/LAK cells recognize and
kill their tumor targets.
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